金陵药业股份有限公司关于全资子公司清算注销完成的公告

Core Viewpoint - The company has completed the liquidation and deregistration of its wholly-owned subsidiary, Huzhou Bangjian Tianfeng Pharmaceutical Co., Ltd., which will no longer be included in the company's consolidated financial statements [1]. Group 1 - The company's board of directors approved the proposal to liquidate and deregister the subsidiary on November 26, 2025 [1]. - The liquidation process has been finalized as confirmed by the Huzhou Market Supervision Administration [1]. - The liquidation and deregistration will not adversely affect the company's overall business development or profitability, nor will it harm the interests of the company and its shareholders [1].